48 results
DEFM14A
AMTI
Applied Molecular Transport Inc.
21 Nov 23
Proxy related to merger
9:16am
or assumes responsibility for a third party’s preclinical or clinical programs, research and development activities, manufacturing and other … factors will apply to it.
AMTI’s decision to discontinue its research and development efforts may not result in the anticipated savings and could
8-K
EX-99.1
AMTI
Applied Molecular Transport Inc.
9 Nov 23
Applied Molecular Transport Reports Third Quarter 2023 Financial Results
4:04pm
data and preparation for NDA submission
Financial Results for the Third Quarter Ended September 30, 2023
Research and development (R&D) expenses. Total … was attributable to our restructuring of operations, related reductions in workforce implemented in March 2023 and discontinuing all research and development
425
AMTI
Applied Molecular Transport Inc.
21 Sep 23
Business combination disclosure
5:12pm
to practice)), customer and supplier lists, improvements, protocols, processes, methods and techniques, research and development information, industry
8-K
EX-2.1
AMTI
Applied Molecular Transport Inc.
21 Sep 23
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement
5:10pm
and techniques, research and development information, industry analyses, algorithms, architectures, layouts, drawings, specifications, designs, plans
8-K
EX-99.1
ctqk72
14 Aug 23
Applied Molecular Transport Reports Second Quarter 2023 Financial Results
4:06pm
8-K
EX-99.1
vd1aju42jg t18s
11 May 23
Applied Molecular Transport Reports First Quarter 2023 Financial Results
4:09pm
8-K
EX-99.1
nnj6earphv1k7
7 Nov 22
Applied Molecular Transport Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:07pm
8-K
EX-99.1
y9w fxehughdabzzg
4 Aug 22
Applied Molecular Transport Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4:10pm
8-K
c4wygdz
18 May 22
Applied Molecular Transport Provides Strategy Update
8:18am
8-K
EX-99.1
zxh8i6wslv4jq js6
9 May 22
Applied Molecular Transport Reports First Quarter 2022 Financial Results and Provides Corporate Update
4:07pm
424B5
c0ity
28 Mar 22
Prospectus supplement for primary offering
9:27pm
10-K/A
hczeuc6vz064ghn6oqfo
25 Mar 22
Annual report (amended)
8:20am